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Engineered therapeutic viruses provide an alternative method for treating infectious diseases, and
mathematical models can clarify the system’s dynamics underlying this type of therapy. In
particular, this study developed models to evaluate the potential to contain human
immunodeficiency virus type 1 (HIV-1) infection using a genetically engineered ‘hunter’ virus that
kills HIV-1-infected cells. First, we constructed a novel model for understanding the progression
of HIV infection that predicted the loss of the immune system’s CD4
+ T cells across time.
Subsequently, it determined the effects of introducing hunter viruses in restoring cell population.
The model implemented direct and indirect mechanisms by which HIV-1 may cause cell depletion
and an immune response. Results suggest that the slow progression of HIV infection may result
from a slowly decaying CTL immune response, leading to a limited but constant removal of
uninfected CD4 resting cells through apoptosis – and from resting cell proliferation that reduces
the rate of cell depletion over time. Importantly, results show that the hunter virus does restrain HIV
infection and has the potential to allow major cell recovery to ‘functional’ levels. Further, the hunter
virus persisted at a reduced HIV load and was effective either early or late in the infection. This




Current therapies with antiviral drugs reduce the human
immunodeficiency virus type 1 (HIV-1) load below
detection and increase the viral targeted cells, the immune
system’s CD4
+ T lymphocytes, yet the infection persists
because of the presence of a latent cellular reservoir (Haase,
1999; Pierson et al., 2000). Further, this therapeutic
approach has significant drawbacks, such as cost, toxicity
and evolution of resistance. An alternative therapy is to use
genetically engineered hunter viruses capable of infecting
and killing HIV-infected cells. This method uses a modified
rhabdovirus having an envelope that binds specifically to
the proteins gp120/41 of HIV-1 on the surface of infected
cells (Schnell et al., 1997). The hunter virus reproduces
through a rapid cytopathic infection that kills the cell and
terminates HIV-1 replication. In vitro studies have shown
that this destruction of infected cells decreased HIV-1 load
by about 1000-fold (Schnell et al., 1997). Also in vitro,a
hunter virus designed for killing simian immunodeficiency
virus (SIV)-infected cells caused SIV load to fall below the
limit of detection. This hunter virus will be used to evaluate
this therapy in vivo in a non-human primate (Okuma et al.,
2006).
Stimulated by these results, we developed a mathematical
model for understanding the dynamics and evaluating the
effectiveness of this treatment approach. Self-replicating
agents have kinetics different from drugs for controlling
diseases (Carlton, 1999; Levin & Bull, 1996; Payne &
Jansen, 2003), requiring an understanding of interactions
among populations of cells and viruses within an
individual. The basis for evaluating the impact of this viral
therapy is determining how the HIV-1 infection progresses
by predicting the loss of CD4 cells. Therefore, this study
first addressed HIV infection by considering several
mechanisms capable of driving cell depletion; subse-
quently, the therapeutic virus was introduced. The analysis
addressed key questions concerning the efficacy of this
therapy. Will a therapeutic virus survive in a system with a
depleted HIV load? When should the agent be introduced?
Will it affect the immune response? How much reduction
in HIV-1 load and recovery in CD4 cells is expected?
Clinical data indicate that after the primary stage, HIV
infection commonly progresses with a slow decline in CD4
cells until the onset of AIDS. The asymptomatic progression
takes an average of 8–12 years in which CD4 cells decline
from about 1000 to 200 cells mm
23 (Fauci & Desrosiers,
1997). The disease then emerges due to a weakened immune
system that makes individuals highly vulnerable to oppor-
tunistic infections. The mechanisms by which HIV-1
infection depletes cells remain a matter of debate (Douek
3Present address: Departamento de Biologı ´a, Universidad Auto ´noma
Metropolitana, DF Me ´xico.
Supplementary material is available with the online version of this paper.
Journal of General Virology (2010), 91, 2513–2523 DOI 10.1099/vir.0.023028-0
023028 G 2010 SGM Printed in Great Britain 2513et al., 2003; Grossman et al., 2002; McCune, 2001). CD4 can
be destroyed directly by the virus – HIV replicates by infecting
and killing activated cells – and by an immune response also
killing infected cells. Another mechanism is a generalized
immune activation and proliferation of CD4 cells (Douek
et al., 2003; Grossman et al., 2002; Hazenberg et al., 2000;
McCune, 2001). These activated cells may also be infected and
killed by HIV or undergo apoptosis (programmed cell death).
A third mechanism is apoptosis of uninfected non-specific
resting or activated CD4 cells through a number of HIV-
mediated mechanisms (Ahr et al., 2004; Finkel et al., 1995;
Gougeon, 2003). Additional factors contributing to further
cell depletion may appear later in the infection, such as more
effective HIV strains for inducing apoptosis or impairment of
lymphoid regenerative capacity (Fauci & Desrosiers, 1997).
The present study addressed HIV infection from the time of
infection through asymptomatic period, under the assump-
tion that these three mechanisms are the main causes of cell
depletion in these decisive stages.
The relative impact of the mechanisms of cell depletion is
incompletely understood, but the combination of them may
eventually overwhelm the ability of CD4 proliferation to
compensate. Immunodeficiency viral infections in other
primates have provided insight into these driving forces.
Natural hosts of SIV exhibit infections with high levels of viral
replication and death of infected cells, but do not develop
progressive depletion of cells (Broussard et al., 2001). These
infections show limited increase in immune activation and
turnover (proliferation and cell death) and no increased
apoptosis (Broussard et al., 2001). Increased apoptosis appears
to be present only in those non-natural hosts of SIV in which
the infection is pathogenic (Davis et al., 1998), suggesting that
apoptosis may be a primary mechanism of cell loss.
This study builds on previous models of HIV infection (De
Boer & Perelson, 1998; Murray et al., 1998; Nowak &
Bangham, 1996; Perelson et al., 1997; Perelson & Nelson,
1999; Phillips, 1996; Wodarz & Jansen, 2001). It differs by
addressing the indirect mechanisms of cell depletion, and
implementing an immune response and dynamics of HIV’s
primary target cell within a single model. Particularly, the
therapeutic infection was based on Revilla & Garcı ´a-Ramos
(2003), who first modelled hunter viruses against HIV and
used a simple framework (i.e. target cell model). Thus, the
present study provides a more coherent formulation of
HIV infection, allowing an evaluation of the therapeutic
approach in a more realistic dynamical system. It makes an
important advance by recognizing and evaluating the
mechanisms underlying HIV dynamics and their implica-
tions in the progression of the infection.
RESULTS
Model
The mathematical model constructed for studying HIV
infection and the therapeutic infection is described in Fig. 1,
showing the interactions between cells and viruses. The
infection system consisted of four interacting dynamic
components: (i) the target cell life cycle, addressing the
Fig. 1. Model description. The diagram shows the interacting
dynamicsofCD4cells(restingx’ andactivatedx),HIVinfection(HIVv
a n dH I V - i n f e c t e dc e l l sy), immune response (l) and therapeutic
infection (hunter virus w and double-infected cells z). Host cell
dynamics: CD4 cells exist as resting or activated cells and activated
cells are the targets for HIV replication. In the absence of HIV, resting
cells x’ are generated at constant rate l, replicate at rate px’/(1+
x’/x’mean), and die at rate dx0. Resting cells x’ are transformed into
activated x at rate mx’, and return to resting stage at rate rx. Activated
cells proliferate at rate p6x and die at rate d6x. HIV-infection: HIV v
infects activated cells x at rate bvx, producing HIV-infected cells y
that die at rate ay. HIV are released from infected cells at rate ky and
from a reservoir at rate vF a n da r er e m o v e da tr a t euv. In the presence
of HIV, the resting cells x’ activate at rate m(1znv)x0 and undergo
apoptosis at rate hvx0; whereas the activated cells x proliferate at
rate p6(1+n6v)x and undergo apoptosis at rate h
0vx.T h e r a p e u t i c
infection: hunter virus w infects HIV-infected cells y, converting them
into double-infected cells z at rate awy. These cells z produce hunter
viruses at rate cz and HIV at rate k1z that cause cell death at rate bz.
Hunter viruses are removed at rate qw. Immune response: both types
of infected cells are killed by CTL response l at rates ily and ilz,
respectively. CTL proliferate at rates gvxl(1– l/lmax)a n dd i ea tr a t ehl.
For simulations, CTL and pathogen flux vF start after HIV reaches 10.
The diagram is formalized into equations by considering incoming
arrows to be positive terms and outcoming arrows to be negative
termsineachequation.Eachequationdescribestherateofchangein
the number of cells or viruses mm
”3 day
”1.
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(ii) the HIV-1 infection, featuring the HIV virus v and
activated-infected CD4 cells y; (iii) the CTL immune
response l; and (iv) the therapeutic infection, incorporating
an engineered-hunter virus w and double-infected CD4
cells z (see Methods).
HIV infection
Numerical simulations generated dynamics of HIV-1
infection along primary and asymptomatic stages compar-
able to experimental data (Cohen et al., 1999; Douek et al.,
2003) (Fig. 2a). Infection initially triggers a rapid change
over a few weeks, in which CD4 cells decline, while HIV
increases towards a peak. A key element in this pattern is
the appearance of a strong CTL response that effectively
reduces HIV load to a low level in a few days. This fall was
faster than observed data (Lindba ¨ck et al., 2000) due to the
system’s simplicity without other HIV compartments. This
temporal plummet in HIV coincides with a partial recovery
in cells for several months until HIV significantly
rebounds. Thereafter, the time-course slows down consid-
erably over several years in which HIV continuously
increases and CD4 cells gradually decay until the critical
density of immunodeficiency of 200 cells mm
23 is reached.
Notice that the model at default values has equilibrium in
the region of immunodeficiency; however, the analysis was
focused on the infection dynamics above this critical
density.
Most models of HIV infection have assumed that cell
depletion results from the killing of CD4-infected cells by
HIV (Murray et al., 1998; Nowak & Bangham, 1996;
Perelson et al., 1997; Phillips, 1996; Stafford et al., 2000;
Wodarz & Jansen, 2001). This study addressed the role of
HIV in triggering apoptosis of both activated and resting
Fig. 2. Temporal dynamics for HIV and therapeutic infection. (a) The progression of HIV infection, indicating the change across
time in the number of CD4 cells x0zx, HIV v and CTL response l. (b) The dynamics of factors contributing to the number of CD4
cells. Panels show rates of loss and gain in number of CD4 cells due to the following causes: HIV killing infected cell ay; CTL
killing HIV-infected cell ily; apoptosis hvx0 (resting), h
0vx (activated); natural mortality dx9 (resting), d6x (activated); activation
m(1znv)x0 (resting); and proliferation l+px9/(1+ x9/x9mean) (resting), p6(1+ n6v)x (activated). ‘- -’ denotes resting and ‘—’
activated cells. (c) The viral therapeutic infection. T1 indicates an introduction of hunter viruses into HIV infection at 400, and T2
at 250 CD4 total cells mm
”3. (d) Detailed dynamics on loss and gain of CD4 cells due to different causes during therapeutic
infection. Panel ‘H-V killing’ indicates loss of HIV-infected cells by hunter virus bz. Initial conditions and parameter values are in
Table 1.
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at the primary HIV infection and speeds cell depletion
dynamics. Fig. 2(b) shows the dynamics underlying the loss
of CD4 cells. Its panels compare the contributions to CD4
depletion caused by HIV and CTL killing cells, apoptosis
(resting and activated cells) and natural mortality, together
with cell transition by activation and cell gain by
proliferation along the progression of the infection
(Fig. 2b). Notice that vertical axis dimensions may vary
along panels. Results indicate that during the asympto-
matic stage the loss of cells by apoptosis is relatively
constant (Fig. 2b, apoptosis panel). This constancy results
from the balanced product of CD4 decay and HIV rise as
time passes (hvx0, h
0vx). In the model activated cells have
greater susceptibility to apoptosis than do resting cells, but
since the majority of CD4 cells are resting, the cell loss
from both stages was significant. At the asymptomatic
stage, apoptosis is the main cause of loss, accounting for far
more cell loss than the HIV and CTL killing of infected
cells. The panel for activation (Fig. 2b) shows a decay in the
number of resting cells activated as time progresses;
however, the rate of cell activation m(1znv)x0 increases
with time following viral load v.
A feature of this model is the addition of a small flux of HIV,
vF. It represents HIV released from cells not represented in the
model, such as macrophages and infected-resting CD4 cells
(Perelson et al., 1997). In the absence of this flux, HIV
plummets to extinction at the acute infection (below 10
28
virions mm
23). A trace flux results in strong oscillations in
CTL and HIV along the transition to asymptomatic infection.
A small flux (0.05–1 virions mm
23 day
21) reduces or
eliminates these oscillations with negligible change in the
subsequentdynamics.NoticethatdampedoscillationsinHIV
load also result from spatially explicit models, which, similar
to our flux will supply virions but from other localities in the
body (Funk et al., 2001). Experimental data indicated that
HIV loadaftertherapid declineremains detectable(Lindba ¨ck
et al., 2000), consistent with a low level flux.
Results showed that CTL did not disappear after primary
infection, but slowly decayed towards immunodeficiency
(Fig. 2a). Without CTL the system reaches equilibrium
within several weeks. Simulations also showed how CTL
strength affects the transient length and number of CD4 at
equilibrium. A slow-growth CTL (small g) led rapidly to
immunodeficiency.Instead,afast-growthCTL(glargerthan
default) delays immunodeficiency or lifts the equilibrium
above the immunodeficiency threshold (and may eliminate
the sharp cell drop at primary infection). In these cases, CTL
decayed very slowly or stabilized at a large number. These
results suggest that a slow decay in CTL strength may delay
immunodeficiency by partially controlling HIV viral load,
thereby slowing the rate of CD4 cell depletion.
Since both CTL and resting cells change slowly during the
asymptomatic stage, inferring cause and effect is not simple.
To investigate if the slow dynamics of resting cells may also
account for the speed of infection progression, we increased
the removalof restingcells.Anincreasein activation ratedid
not lead to cell depletion; however, a rise in death rate or
apoptosis speeds cell loss in comparison to default.
Assuming that natural mortality does not change with
infection, we further investigated apoptosis. An infection
with no resting cell apoptosis led to 93% normal cell count,
which indicates that the default CTL is capable of a major
control of non-apoptotic HIV strains. Afterward, cell counts
at equilibrium decreased in proportion to the severity of
apoptosis (i.e. 63 to 44% normal levels for half to three-
quarters default apoptosis, respectively).
Since CD4 cell proliferation does not balance losses in HIV
infection, a daily deficit accumulates over time until
reaching immunodeficiency. By early asymptomatic infec-
tion this deficit is only a fraction of the resting cells removed
by apoptosis, indicating the role of proliferation in
ameliorating the cell loss and slowing the dynamics to the
infection equilibrium. Also at early asymptomatic stage, the
CTL strength (i.e. number of CTL cells) sets the HIV load
and thus, the intensity of damage through apoptosis. At that
time, CTL was partially effective and further deteriorated
over time according to resting cell count (since help from
activated cells was proportional to resting cell count). As
CTL decayed, the HIV load increased; however, apoptosis
remained approximately constant and became the major
removal of cells at immunodeficiency. Consequently, these
results suggest that the slow progression of HIV infection
may result from a slowly decaying CTL, leading to a limited
but constant removal of resting cells through apoptosis, as
wellas from therestingcell proliferationthat ameliorates the
cell depletion rate over time.
Parameter values are subject to some degree of uncertainty
and variability (Supplementary Table S1, available in JGV
Online). In this respect, simulations showed that parameter
values differing ¡6% from defaults yielded qualitatively
similar results in leading to immunodeficiency. This
relatively narrow consistency range indicated sensitive
parameters and suggested the presence of non-linear
stabilizing mechanisms in vivo that the current model did
not include. We further explored a broader parameter space
that simultaneously sampled all the parameter values within
plausible ranges (Supplementary Table S2, available in JGV
Online). This analysis showed a wider range of progression
varying from minor cell losses through the asymptomatic
period to immunodeficiency by year 3, which corresponds
to theinterquartile range around the progressionfor median
values (Supplementary Fig. S1, available in JGV Online).
Thus, the model predicts substantial deviation in the
progression when both host and pathogen exhibit variation.
Notice that high variation in infection progression has been
observed within populations (Concerted Action on
SeroConversion to AIDS and Death in Europe, 2000).
Hunter virus therapeutic infection
The analysis evaluated therapeutic introductions of hunter
viruses early or late in HIV infection (at 400 or 250 cells
G. Garcı ´a-Ramos, D. Castillo and P. H. Crowley
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23, respectively). In both cases, the effect of delivering a
hunter virus into the HIV infection is to halt CD4 cell
depletion and generate a rebound over 2/3 of healthy levels
(Fig. 2c). For the default parameter values, the recovery is
64% of the CD4 cell normal level. The rebound trajectory
follows a saturation curve with initial speeds proportional
to the magnitude of CD4 reduction. After the first year of
therapy, more than 50% of the expected recovery is
reached. The speeds of recovery were comparable to rises
after highly active antiretroviral therapy (HAART) treat-
ment where cell count typically increases rapidly for a few
months, followed by more gradual rises until a normal
value may be reached (Geng & Deeks, 2009; Hunt et al.,
2003; Vrisekoop et al., 2008). These clinical data indicate
that the immune system is capable of producing substantial
numbers of cells even after advanced immune depletion.
This supports the model’s assumption that the parameters
stay constant during disease progression and that the
variables are capable of capturing the dynamic process.
Thus, infection progression constitutes a slow transient
from the uninfected to the infected equilibrium, which
could be substantially reversed with hunter viruses. Cases
of severe depletion with compromised regenerative capa-
city may change parameter values (i.e. resting cell growth
rate) and may thus lead to a reduced therapy efficiency.
The HIV load that coexists with the hunter virus is
comparable to the load at the setpoint – at the time of the
largest recovery of CD4 from acute infection (Fig. 2c). The
CTL response rapidly decays after the hunter virus is
delivered (Fig. 2c), suggesting that this immune response
will not persist with the hunter virus under this therapy.
Panels in Fig. 2(d) show that the hunter virus caused a
reduction in the number of CD4 killed by HIV and
apoptosis and in proliferation of activated cells. The hunter
virus allowed mortality and proliferation of resting cells to
approach normal values.
Delivery time. The delivery time for a successful
therapeutic introduction was predicted with the ‘basic
reproductive ratio’ Rw
0 (Nowak & May, 2000). Rw
0 describes
the number of secondary infections produced by a single
infection, and when this ratio is larger than one (Rw
0 .1),







; see symbols in Table 1 and derivation in
Supplementary Material, available in JGV Online). This
ratio is commonly evaluated when the system to invade is
at equilibrium (i.e. equations set to zero in Fig. 1),
requiring the number of HIV-infected cells y and CTL l in
that situation. However, this calculation is of limited use
for therapy since the equilibrium is located within the
region of immunodeficiency (i.e. below 200 cells mm
23).
The basic reproductive ratio, indicating the invasion
suitability throughout the course of the infection is
shown in Fig. 3. In Fig. 3, Rw
0 was estimated by replacing
the values of y(t) and l(t) through time. Fig. 3 shows two
shaded areas for successful invasion concerning the
establishment and persistence of the therapeutic
infection: (i) a brief interval during primary infection,
and (ii) shortly before the setpoint and thereafter.
Introductions at the primary infection reached the same
equilibrium as introductions in asymptomatic infection
but in a smooth fashion with a small HIV peak and CD4
fall. These results indicate that the hunter virus can be
introduced anytime after reaching a threshold of infected
cells before the peak of infection or within a few months of
infection, indicating its capability of surviving at limited
and severe CD4 depletion.
Efficiency. The number of recovered CD4 cells measured
the efficiency of the therapy, and it depended on the hunter
virus vital rates. Recovery increased with increasing
infectivity a and production rate c, and with reducing
hunter virus removal rate q. Fig. 4(a) shows that cell
recovery follows a saturating curve as the product of
infectivity a and hunter virus production c increases –
relative to the corresponding product for HIV (i.e. ac/bk:
infectiveness amplification). For example, an efficient
recovery over 600 CD4 cells (i.e. 60% healthy level)
required that infectiveness of the hunter virus be amplified
155 times with respect to HIV (Fig. 4a). This requires, for
example, a hunter virus infectivity of a50.02 and
production c51550; or a50.004 and c57750 with other
parameters at defaults. Notice in Fig. 4(a) that cell recovery
is very sensitive to infectiveness amplification increments
for values below 300, suggesting a range of high
profitability. Another factor that proportionally increases
recovery is a lowering hunter virus removal rate q in
relation to HIV u (q/u). The default values assumed a
quotient q/u52/3, though, smaller quotients lessen
infectiveness amplification for a cell recovery level. For
instance, an order of magnitude reduction in default
removal rate q increased the efficiency of cell recovery from
64 to 89%. On the other hand, the HIV population is
affected inversely to CD4 cells (Fig. 4b), and the curve
shifts downwards, increasing infectivity a and production
of hunter virus per cell c. In Fig. 4(b), the lines bifurcate at
lower values of c, indicating a region of values where the
therapy leads to oscillations in HIV. These oscillations
belong to a periodic attractor with one fundamental
frequency (for default values at 45 days), indicating that
HIV periodically fluctuates over time with maxima
amplitude given by bottom and top line values (Fig. 4b)
(Liu, 2003). This dynamical behaviour is also observed for
the hunter virus (Fig. 4c) but is absent in CD4. One cost of
this viral therapy is measured in terms of the population
size of hunter virus maintained at equilibrium; and it
ranged from few dozens (default) to few hundreds. This
cost decreases with larger infectivity and lower production
rate of hunter viruses (Fig. 4c). Notice that the viral flux, as
well as HIV released from double-infected cells promotes
stability of the therapeutic infection by reducing the
amplitude of oscillations in both viruses. The therapeutic
efficacy was evaluated on a typical progression of HIV-1
infection. Results were qualitatively similar to default
therapeutic infection when parameter values for HIV
Hunter viruses and HIV-1 infection
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HIV proliferation k and CTL proliferation g) were changed
at least within a factor of 0.5–1.5. When all the model
parameter values varied simultaneously within ranges
around defaults (Supplementary Material), the mean
CD4 recovery was about 46% of the total healthy level
(95% CI, 44–47%) (measured in resting cells at day 3000;
86% of simulations rebound from introductions at 300
cells; and HIV load dropped to 7.6% [95% (CI, 6.9–8.2%)
upon delivery]. This recovery was smaller than default
therapeutic infection (64% total, 62% resting), suggesting
that maximum recovery may not be reached for all of the
simulations, as well as asymmetrical effects of varying
parameters values [i.e. recovery followed a saturating curve
more sensitive towards smaller infectiveness-amplification
values (Fig. 4a)].
Table 1. Basic parameter values and initial conditions used in simulations
Parameter (c, cells mm
”3; v, virions mm
”3; d, day) Value Reference(s)
l Production rate of resting cell (cd
21) 1 Di Mascio et al. (2006); Kaufmann et al. (2001)
p Replication rate of resting cell (d
21) 0.0045 Kaufmann et al. (2001)
pu Replication rate of activated cell healthy condition
(d
21)
0.02 Ribeiro et al. (2002)




0.007 Ribeiro et al. (2002)
d Death rate of resting cell (d
21) 0.003 Kaufmann et al. (2001); Michie et al. (1992);
Richman (2000)
du Death rate of activated cell (d
21) 0.03 Kaufmann et al. (2001); Stafford et al. (2000)
a Death rate of HIV-infected cell (d
21) 0.33 Davenport et al. (2004); Perelson et al. (1996);
Phillips (1996)
b Death rate of double-infected cell (d
21) 2 Schnell et al. (1997)
m Activation rate healthy condition (d
21) 0.0011 Kaufmann et al. (2001)
mn Activation rate from infection (v
21d
21) 4.4610
25 Kaufmann et al. (2001); Phillips (1996)
r Deactivation rate (d
21) 0.026 Kaufmann et al. (2001)
b HIV infection rate (v
21d
21) 0.004 Phillips (1996); Layne et al. (1989); Murray et
al. (1998)
h Apoptotic rate of resting cell* (v
21d
21) 0.00044
h Apoptotic rate of activated cell* (v
21d
21) 0.005
k HIV production rate by HIV-infected cell (vc
21d
21) 50 Dimitrov et al. (1993); Haase (1999)
k1 HIV production rate by double-infected cell (vc
21d
21) 5 Schnell et al. (1997)
u HIV removal rate (d
21) 3 Perelson et al. (1996); Markowitz et al. (2003);
Ramratnam et al. (1999); Perelson et al. (1997)
vF HIV flux rate (vd
21) 0.84
a Hunter virus infection rateD (v
21d
21) 0.02
c Hunter virus production rate (vc
21d
21) 1800 Schnell et al. (1997)
q Hunter virus removal rateD (d
21)2
g CTL proliferation rate (v
21c
21d
21) 0.00038 Kaufmann et al. (2001); Davenport et al. (2004)
h CTL death rate (d
21) 0.025 Ogg et al. (1999)
i CTL killing rate (c
21d
21) 0.02 Altes et al. (2002); Appay et al. (2002);
Klenerman et al. (1996); Mandl et al. (2007)
lmax Maximum CTL number (c) 500 Appay et al. (2002); Betts et al. (2001); Lindba ¨ck
et al. (2000)
x9mean Average resting CD4 cell number (c) 970 Hellerstein et al. (2003); Hunt et al. (2008)
Variable initial value
x9 CD4 resting cell number (c) 970
x CD4 activated cell number (c) 30 .
y HIV-infected cell number (c) 0
z Double-infected cell number (c) 0
v HIV number (v) 5610
25
w Hunter virus number (v) 0.1
l CTL number (c) 0.03
*Inferred.
DInferred in relation to HIV. Supplementary Table S1 compares and justifies parameter values.
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This study satisfactorily predicted the typical course of HIV
infection from infection through asymptomatic stage. It
was able to capture from the initial viraemia peak and drop
in CD4 cells to the strong CTL response and temporary
recovery of cells and HIV rebound. It also described the
asymptomatic stage, with viraemia slowly rising and CD4
slowly decaying towards immunodeficiency. Most models
of HIV infection address short-term dynamics, though,
long-term progression has been studied (Bajaria et al.,
2002; Duffin & Tullis, 2002; Nowak et al., 1990; Stilianakis
et al., 1997; Stilianakis & Schenzle, 2006). These models
generally have considered simplistic assumptions about the
infection system and earlier mechanisms of cell depletion.
The present study analysed the impact of HIV on CD4 cells
through recently proposed mechanisms (i.e. generalized
activation and increased apoptosis), as well as an immune
response. Our analysis indicated that an efficient CTL
accounts for most of the loss of infected cells in the acute
infection, and that CTL killing and virus cytopathicity
contribute similarly to the loss of cells during the
asymptomatic phase. These results are consistent with a
comparison for the loss of infected cells by McMichael &
Phillips (1997).
Our model also found that the loss of uninfected cells
(either resting or activated) by apoptosis is a major cause of
cell loss during acute infection. This important effect
persisted through the asymptomatic stage and was several
times larger than other causes of cell loss. Moreover, the
cell loss by apoptosis in the asymptomatic stage followed a
relatively constant pattern independent of the depletion
level. A similar steady pattern for apoptosis at asymptomatic
infection is suggested by Gougeon (2003). In our model,
activated-uninfected cells had a single term for apoptosis,
and thus, the two indirect mechanisms by which HIV may
lead to CD4 depletion (i.e. generalized activation and
enhanced apoptosis) overlapped. Nonetheless, apoptosis of
resting cells alone may account for more of half of the cell
loss, pointing out the importance of increased apoptosis.
Furthermore,thisstudy suggeststhat theslowprogression of
HIV infection may result from a slowly decaying CTL
response, leading to a limited but constant removal of
uninfected resting cells through apoptosis, and from resting
cell proliferation that ameliorates the rate of cell depletion
over time.
The proposed therapeutic hunter virus consisted of a
highly prolific, short life cycle, cytopathic virus for
targeting HIV-infected cells (Schnell et al., 1997). Results
indicated that it was efficient in controlling HIV load and
allowing the recovery of the immune system’s CD4 cells to
high levels (64% at default values) without eliminating
HIV-1. The therapeutic virus establishes readily, since it
survives in a system with a depleted HIV load. It can persist
if introduced either at an early stage or an advanced stage
of CD4 depletion. This therapy stabilizes HIV at low levels,
resulting in no further depletion of CD4 associated with
the progression of HIV infection. The CTL rapidly decays
after the hunter virus is delivered (Fig. 2c), suggesting that
this immune response will not coexist with the hunter virus
under this therapy. This indicates that the hunter virus and
CTL are strong competitors for the same resource (HIV-
infected cells); and the elimination of the less efficient
competitor follows the competitive exclusion principle. By
selecting a fast-growth CTL (g .1.56default), the model
generated behaviour where the CTL dominated and the
hunter virus did not invade.
Our results are consistent with those of Revilla & Garcı ´a-
Ramos (2003). There are structural differences between the
2003 and the present model; further the current model
evaluated a more efficient hunter virus with adjustments in
parameter values for better fit to clinical data. Nevertheless,
considering identical values when it was possible and using
equations 3 and 5 from Revilla & Garcı ´a-Ramos (2003), the
current model showed a moderate enhancement of cell
recovery and a lower reduction in HIV after therapy. The
target cell (2003) model produced higher HIV loads,
suggesting a greater conversion of cell number into viruses,
which may result from an entire pool of cells that was
activated and without apoptosis.
Therefore, the results reported here indicate that the
beneficial effects of hunter viruses are sustained under a
more realistic and general HIV infection dynamics. The
present study incorporated resting cells for quantifying the
cycling pattern between resting and activated stages over
time, as well as the mortality of uninfected-resting cells due
to HIV. In particular, the implementation of a CTL response
predicted long-term progression of the HIV infection that
was not observed by Revilla & Garcı ´a-Ramos (2003), where
the dynamics reached equilibrium rapidly. This indicated
that the therapeutic agent can establish along the progres-
sion of HIV infection, besides the equilibrium at immuno-
Fig. 3. Basic reproductive ratio Rw
0 for the therapeutic infection
throughout the HIV infection. For Rw
0 larger than one, the hunter
virus can successfully invade an HIV infection (shaded areas).
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viruses recovered 60% cell healthy level with a 155 ratio for
the production by infection rate of the hunter virus in
relation to the same product for HIV (ac/bk, Fig. 4a).
However, this ratio decreased with lower hunter virus
removal rates with respect to HIV (i.e. the ratio fell one
order of magnitude when hunter virus removal rates are one
order of magnitude lower than in HIV. The envelopes of the
hunter viruses display human proteins that may lead to very
low removal rate).
Alternative strategies using viruses for controlling HIV
replication consider the defective interfering viruses (DIVs)
and conditional replicating anti-HIV gene therapy viruses
(Morris et al., 2004; Westerhout et al., 2006). DIVs and
gene therapy viruses to treat viral infections have been
studied theoretically, and particularly interesting are the
analyses by Nelson & Perelson (1995) targeting HIV-
infected cells and Weinberger et al. (2003) for uninfected
cells using ‘crHIV’ viruses (discussed in Supplementary
Material). These studies relied on different assumptions
(i.e. mechanisms by which HIV causes cell death, target
cells and dynamics and parameter values) and therefore,
only rough comparisons are possible. These studies suggest
that replicate-competent modified viruses may have long-
term therapeutic potential. The efficiencies of these
strategies depended on the underlying dynamics of
pathogen and therapeutic infections and thus, on the
amplification of the therapeutic infection relative to HIV.
In particular, the hunter viruses have advantages over using
DIV- and HIV-derived vector viruses, since the hunter
virus could be selected from highly prolific viruses without
the restrictions of using a related virus (i.e. vesicular
stomatitis virus may release 10
5 virions per cell; Rose &
Whitt, 2001). Moreover, a hunter virus may be advan-
tageous over crHIV, since it produces numerous crHIV-
infected cells (~3/4 cells, Fig. 2 in Weinberger et al., 2003)
that may generate a CTL response. The hunter virus
approach has the additional advantage of the relevant type
of hunter virus may occur in the cell cytoplasm,
eliminating the issue of insertion into the nucleus.
A matter of concern of this hunter virus therapy is the
permanent population of virions thus created. Hunter
viruses are expected to replicate only in HIV-infected cells,
and because their envelopes carry human proteins, they are
expected to generate a minimal immune response. Notice
that the alternative strategies discussed also involved
significant populations of therapeutic agents. Nonetheless,
inserted or circulating viruses are not necessarily an issue
of concern. For instance, many species of primates carry
high viral load of SIV without apparently affecting
individual survival (Holzammer et al., 2001). Moreover, a
conditionally replicating anti-HIV-1 gene therapy virus
Fig. 4. Therapy effects on number of CD4 cells, HIV and hunter
viruses at equilibrium with varying hunter virus vital rates. (a)
Efficiency in recovering CD4 cells in terms of an amplification ratio
relating therapeutic and HIV infection parameters. This ratio relates
the product of infectivity and production for hunter viruses to the
corresponding product for HIV (ac/bk). (b) HIV load after therapy.
Shaded areas describe maximum amplitude oscillations. Stars
correspond to HIV load after therapy depicted in Fig. 2(b).
Horizontal line indicates HIV load at equilibrium in absence of
hunter virus. (c) Cost of therapy in terms of population size of
hunter virus. Default values are indicated with stars.
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safe regarding mutagenesisand recombination (Levine et al.,
2006). Viruses offer major new opportunities to treat
diseases, and the development of efficacious therapies
requires a full understanding of dynamics and efficiencies,
as well as safety.
This kind of modelling analysis is an essential step in the
development of biologically dynamic therapy whenever the
constraints on experimentation are severe, as for HIV. This
analysis presents a number of predictions for experimental
examination. The key role of apoptosis and resting cell
proliferation in the gradual loss of CD4 in the simulations
argues strongly for empirical documentation of these
features (i.e. quantification with sufficient precision and
throughout infection). Complementary SIV studies in vitro
and in vivo will allow more extensive experimental
manipulation. For example, the SIV-system can be used
to test whether the hunter viruses would replace the CTL
response, as our model predicts. As well, it could assess if
the therapeutic effect is largely independent of the time
since infection. This system could also test the impact of
quantitative features of a hunter virus on disease
development, such as Rw
0 and infectiveness amplification,
while addressing the basic question of whether the hunter
virus can sustain high CD4 cell levels in vivo and halt
disease progression. In particular, the results highlight the
importance of raising the infectiveness amplification ratio,
and our findings predict that this ratio could be better
improved by increasing the infection rate of hunter viruses
via lowering their viral load. Future advances in the uses of
dynamic biological therapies will surely hinge on our
ability to pursue experimentation and empirical observa-
tions informed by (and informing) further development of
realistic simulation models.
METHODS
The model was formulated in differential equations (Fig. 1) and
analysed numerically using MATLAB. Parameters were time independ-
ent and are described in Table 1. The rationale used for representing
the infections is explained in the Supplementary Material. The model
assumed that HIV causes CD4 death through the killing of activated-
infected cells (Haase, 1999), and indirectly by inducing a generalized
immune activation [i.e. HIV increases activation, cell division and
activation-induced cell death (Grossman et al., 2002)], and enhanced
apoptosis [i.e. HIV-mediated mechanisms that induce death of
uninfected CD4 either activated or resting (Gougeon, 2003)]. The
indirect mechanisms were implemented by considering that activa-
tion, activated cell expansion, and apoptosis of uninfected resting and
activated cells were dependent on HIV load.
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